According to a recent study, tea consumption offers protective effects on mortality among patients with chronic kidney disease.

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular ...

Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with ...

According to a 2019 review, up to 84% of people with end stage chronic kidney disease develop pruritus. The authors state that recent advancements in dialysis treatments have helped bring the ...

Drinking tea may help people with chronic kidney disease (CKD) live longer, according to a study published on January 13 in ...

The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

CKD can lead to severe complications like anemia, uremic gastroenteritis, and renal secondary hyperparathyroidism. Early ...

Last month, the European Medicines Agency allowed Novo to add risk reduction for events related to kidney disease to the ...